RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Sparky, Cortex still seems to be considered a stale story, though some good news will hopefully change that. Many in the pharma world probably stopped following the stock after the CX-717 artifact/clinical hold problems, and have no idea of the progress since then. Being mired at .15 cent range also limits who will bother to follow a stock.

But one could imagine a strong scenario for Cortex by this time next year. I figure more money will be needed by ~ late Spring next year, but there is apparent interest in ex-US partnering for ADHD (pharmas are giving input into the trial design), plus the return of the Schizo/Depression rights could lead to a broader partnership in 2011. Then there's the SA results which, if strong, create an additional area of partnering interest. Cortex has a TON of new compounds from the new compound families, both high and low impact, albeit still preclinical stage. Hopefully we can get some of these cranked up in 2011 as finances improve.
First on the list are the lead high impact CX-1846, and the low impact CX-2076.

Also, in the Sept presentation slides there appeared to be renewed interest in 'inlicensing late stage assets for CNS orphan indications, around which new funding can be raised'. One could imagine a scenario where many of the low impact Ampakine indications are outlicensed (ADHD, Schizo, Depression, etc), and then Cortex would concentrate on the high impacts, plus an inlicensed late stage non-Ampakine orphan program.